产品管线方面，云顶新耀将聚焦肾科、自身免疫、急重症、心血管及眼科等核心方向，通过引进创新资 产与自主研发并行推进，到2030年形成高价值产品组合，并拓展其他蓝海领域的大单品。到2030年，云 顶新耀计划将商业化产品数量提升至20款以上。 经济观察网12月15日，云顶新耀发布2030年发展战略，公司计划到2030年实现收入规模超过150亿元。 其中现有管线销售收入约90亿元，新引进管线销售收入约60亿元，并探索潜在对外授权(License-out)收 入。 董事会主席吴以芳表示，未来五年，公司将聚焦"BD合作+自研"双轮驱动，依托科学与市场洞察，推动 战略领域形成N+X产品组合，把握蓝海大单品机遇。公司计划通过已经建立的BD能力和康桥生态，每 年引进3-5个中后期重磅产品，依托自身精干高效的商业化团队实现每个产品医保后三年销售达峰。 ...

Core Viewpoint - The company has announced its 2030 development strategy, focusing on dual-driven growth through "BD collaboration + self-research" to enhance product pipelines and maximize commercial platform value [1][2]. Group 1: 2030 Development Strategy - The 2030 strategy outlines a five-year plan aimed at solidifying the company's core therapeutic areas and advancing innovative drug research and commercialization [1]. - The strategy emphasizes the importance of BD collaboration and self-research to create both certain and growth-oriented value [1][2]. - The company aims to introduce 3 to 5 late-stage significant products annually through established BD capabilities and partnerships, targeting peak sales within three years post-reimbursement [2]. Group 2: Shareholder Actions - Key executives and major shareholders have collectively increased their holdings by purchasing 846,700 shares for over HKD 38 million, averaging HKD 45.01 per share [1]. Group 3: Commercialization and Growth - The company has established a commercial system driven by scientific and market insights, which has led to significant sales growth, exemplified by a slow disease medication achieving over CNY 1 billion in sales in its first full commercial year [3]. - The company plans to leverage its commercialization experience in nephrology and anti-infection to expand into other therapeutic areas such as immunology, ophthalmology, critical care, and cardiovascular diseases [3]. - The company is committed to addressing unmet medical needs globally, enhancing its competitiveness in the innovative drug sector [3].